• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A Look Into Healthcare Sector Value Stocks

    3/11/24 10:43:58 AM ET
    $ALKS
    $INMD
    $KPRX
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ALKS alert in real time by email

    Understanding Value Stocks

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    The following stocks are considered to be notable value stocks in the healthcare sector:

    1. Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 0.84
    2. Procaps Gr (NASDAQ:PROC) - P/E: 6.16
    3. InMode (NASDAQ:INMD) - P/E: 9.55
    4. Alkermes (NASDAQ:ALKS) - P/E: 9.56
    5. Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 7.97

    Kiora Pharmaceuticals saw a decrease in earnings per share from -0.79 in Q2 to $-0.89 now. Procaps Gr saw a decrease in earnings per share from 0.27 in Q2 to $0.08 now. Most recently, InMode reported earnings per share at $0.71, whereas in Q3 earnings per share sat at $0.61. Alkermes's earnings per share for Q4 sits at $0.48, whereas in Q3, they were at 0.64. This quarter, Syros Pharmaceuticals experienced a decrease in earnings per share, which was $-1.3 in Q2 and is now $-1.43.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $ALKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS
    $INMD
    $KPRX
    $PROC

    CompanyDatePrice TargetRatingAnalyst
    Alkermes plc
    $ALKS
    11/11/2025$50.00Buy
    Truist
    Alkermes plc
    $ALKS
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    Alkermes plc
    $ALKS
    9/3/2025$44.00Overweight
    Wells Fargo
    Alkermes plc
    $ALKS
    7/15/2025$43.00Buy
    Goldman
    Alkermes plc
    $ALKS
    6/17/2025$42.00Neutral → Buy
    UBS
    Alkermes plc
    $ALKS
    5/28/2025$45.00Buy
    Needham
    InMode Ltd.
    $INMD
    4/29/2025Buy → Neutral
    BTIG Research
    InMode Ltd.
    $INMD
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ALKS
    $INMD
    $KPRX
    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director and CEO, Alkermes plc Pops Richard F was granted 149,580 units of Ordinary Shares and covered exercise/tax liability with 62,230 units of Ordinary Shares, increasing direct ownership by 7% to 1,377,740 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/6/26 7:14:03 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Commercial Officer Nichols Christian Todd was granted 21,127 units of Ordinary Shares and covered exercise/tax liability with 6,389 units of Ordinary Shares, increasing direct ownership by 17% to 100,946 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/6/26 7:13:20 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Operating Officer Jackson Blair Curtis was granted 28,810 units of Ordinary Shares and covered exercise/tax liability with 8,626 units of Ordinary Shares, increasing direct ownership by 10% to 221,552 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/6/26 7:12:38 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    SEC Filings

    View All

    Alkermes plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/12/26 7:37:57 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by InMode Ltd.

    S-8 - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:38:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 20-F filed by InMode Ltd.

    20-F - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:33:27 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Haas Jason bought $161,240 worth of shares (100,000 units at $1.61), increasing direct ownership by 407% to 124,552 units (SEC Form 4)

    4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

    9/12/24 5:00:03 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Chee Conley bought $160,680 worth of shares (100,000 units at $1.61), increasing direct ownership by 444% to 122,504 units (SEC Form 4)

    4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

    9/12/24 5:00:03 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Stengone Carmine N. bought $4,600 worth of shares (1,250 units at $3.68) (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    9/12/24 6:32:55 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Alkermes Plc with a new price target

    Truist initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $50.00

    11/11/25 8:03:02 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Alkermes Plc with a new price target

    Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00

    9/3/25 8:26:50 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

    — Augments Alkermes' Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension — — Expected to be Accretive in 2026 — — Positions the Combined Organization to Accelerate Innovation and Leadership in Development of Treatments for Sleep Disorders and Other Neurological Disorders — Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced Alkermes' completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel's FDA-approved product, LUMRYZ®, to Alkermes' commercial portfolio, and

    2/12/26 7:30:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visit

    2/11/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

    MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

    12/20/24 4:53:03 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:28:08 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    $INMD
    $KPRX
    $PROC
    Financials

    Live finance-specific insights

    View All

    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visit

    2/11/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

    Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and ot

    1/8/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care